RATIONALE: Vascular endothelial growth factor receptor (VEGFR) inhibition increases ceramides in lung structural cells of the alveolus, initiating apoptosis and alveolar destruction morphologically resembling emphysema. The effects of increased endogenous ceramides could be offset by sphingosine 1-phosphate (S1P), a prosurvival by-product of ceramide metabolism. OBJECTIVES: The aims of our work were to investigate the sphingosine-S1P-S1P receptor axis in the VEGFR inhibition model of emphysema and to determine whether stimulation of S1P signaling is sufficient to functionally antagonize alveolar space enlargement. METHODS: Concurrent to VEGFR blockade in mice, S1P signaling augmentation was achieved via treatment with the S1P precursor sphingosine, S1P agonist FTY720, or S1P receptor-1 (S1PR1) agonist SEW2871. Outcomes included sphingosine kinase-1 RNA expression and activity, sphingolipid measurements by combined liquid chromatography-tandem mass spectrometry, immunoblotting for prosurvival signaling pathways, caspase-3 activity and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assays, and airspace morphometry. MEASUREMENTS AND MAIN RESULTS: Consistent with previously reported de novo activation of ceramide synthesis, VEGFR inhibition triggered increases in lung ceramides, dihydroceramides, and dihydrosphingosine, but did not alter sphingosine kinase activity or S1P levels. Administration of sphingosine decreased the ceramide-to-S1P ratio in the lung and inhibited alveolar space enlargement, along with activation of prosurvival signaling pathways and decreased lung parenchyma cell apoptosis. Sphingosine significantly opposed ceramide-induced apoptosis in cultured lung endothelial cells, but not epithelial cells. FTY720 or SEW2871 recapitulated the protective effects of sphingosine on airspace enlargement concomitant with attenuation of VEGFR inhibitor-induced lung apoptosis. CONCLUSIONS: Strategies aimed at augmenting the S1P-S1PR1 signaling may be effective in ameliorating the apoptotic mechanisms of emphysema development.
RATIONALE: Vascular endothelial growth factor receptor (VEGFR) inhibition increases ceramides in lung structural cells of the alveolus, initiating apoptosis and alveolar destruction morphologically resembling emphysema. The effects of increased endogenous ceramides could be offset by sphingosine 1-phosphate (S1P), a prosurvival by-product of ceramide metabolism. OBJECTIVES: The aims of our work were to investigate the sphingosine-S1P-S1P receptor axis in the VEGFR inhibition model of emphysema and to determine whether stimulation of S1P signaling is sufficient to functionally antagonize alveolar space enlargement. METHODS: Concurrent to VEGFR blockade in mice, S1P signaling augmentation was achieved via treatment with the S1P precursor sphingosine, S1P agonist FTY720, or S1P receptor-1 (S1PR1) agonist SEW2871. Outcomes included sphingosine kinase-1 RNA expression and activity, sphingolipid measurements by combined liquid chromatography-tandem mass spectrometry, immunoblotting for prosurvival signaling pathways, caspase-3 activity and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assays, and airspace morphometry. MEASUREMENTS AND MAIN RESULTS: Consistent with previously reported de novo activation of ceramide synthesis, VEGFR inhibition triggered increases in lung ceramides, dihydroceramides, and dihydrosphingosine, but did not alter sphingosine kinase activity or S1P levels. Administration of sphingosine decreased the ceramide-to-S1P ratio in the lung and inhibited alveolar space enlargement, along with activation of prosurvival signaling pathways and decreased lung parenchyma cell apoptosis. Sphingosine significantly opposed ceramide-induced apoptosis in cultured lung endothelial cells, but not epithelial cells. FTY720 or SEW2871 recapitulated the protective effects of sphingosine on airspace enlargement concomitant with attenuation of VEGFR inhibitor-induced lung apoptosis. CONCLUSIONS: Strategies aimed at augmenting the S1P-S1PR1 signaling may be effective in ameliorating the apoptotic mechanisms of emphysema development.
Authors: Guy M L Meno-Tetang; Hongshan Li; Suzette Mis; Nancy Pyszczynski; Peter Heining; Philip Lowe; William J Jusko Journal: Drug Metab Dispos Date: 2006-06-02 Impact factor: 3.922
Authors: Kelly S Schweitzer; Steven X Chen; Sarah Law; Mary Van Demark; Christophe Poirier; Matthew J Justice; Walter C Hubbard; Elena S Kim; Xianyin Lai; Mu Wang; William D Kranz; Clinton J Carroll; Bruce D Ray; Robert Bittman; John Goodpaster; Irina Petrache Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-05-15 Impact factor: 5.464
Authors: Krzysztof Kamocki; Mary Van Demark; Amanda Fisher; Natalia I Rush; Robert G Presson; Walter Hubbard; Evgeny V Berdyshev; Swetlana Adamsky; Elena Feinstein; Aneta Gandjeva; Rubin M Tuder; Irina Petrache Journal: Am J Respir Cell Mol Biol Date: 2012-09-28 Impact factor: 6.914
Authors: Melpo Christofidou-Solomidou; Ralph A Pietrofesa; Evguenia Arguiri; Kelly S Schweitzer; Evgeny V Berdyshev; Maureen McCarthy; Astrid Corbitt; Joshua S Alwood; Yongjia Yu; Ruth K Globus; Charalambos C Solomides; Robert L Ullrich; Irina Petrache Journal: Am J Physiol Lung Cell Mol Physiol Date: 2014-12-19 Impact factor: 5.464
Authors: Russell P Bowler; Sean Jacobson; Charmion Cruickshank; Grant J Hughes; Charlotte Siska; Daniel S Ory; Irina Petrache; Jean E Schaffer; Nichole Reisdorph; Katerina Kechris Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405